3-arm, Double-blind, Non-inferiority Study followed by an Open-label Extension, Randomized
Recruiting
International, VIC
Relapsing MS, Relapsing remitting MS
Efficacy and safety of ofatumumab and siponimod compared to fingolimod in pediatric patients with multiple sclerosis
Between 10 to <18 years of age (i.e., have not yet had their 18th birthday) at randomization Diagnosis of multiple sclerosis EDSS score of 0 to 5.5, inclusive At least one MS relapse/attack during the previous year or two MS relapses in the previous two years prior or evidence of one or more new T2 lesions within 12 months
Participants with progressive MS
Participants with an active, chronic disease of the immune system other than MS
Participants meeting the definition of ADEM
Participants with severe cardiac disease or significant findings on the screening ECG.
Participants with severe renal insufficiency
Already started
Novartis Pharmaceuticals
Phone Number:
1-888-669-6682
Email: novartis.email@novartis.com
ClinicalTrials.gov ID NCT04926818
Worldwide
Yes
15/09/2023
"*" indicates required fields